Overview

The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus

Status:
Unknown status

Trial end date:
2018-03-01

Target enrollment:

Participant gender:

Summary

This study is designed to validate the hypothesis that the treatment of rosuvastatin could increase the score of Calcification of Coronary artery(CAC) density in coronary artery disease(CAD) patients with diabetes mellitus.CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.

Phase:

Phase 4

Details

Lead Sponsor:

Sir Run Run Shaw Hospital

Treatments:

Rosuvastatin Calcium